Literature DB >> 15115784

Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat--possible implications for the pathophysiology of headaches.

Stansilav Koulchitsky1, Michael J M Fischer, Roberto De Col, Philipp M Schlechtweg, Karl Messlinger.   

Abstract

Nitric oxide (NO) is suggested to play a causative role in the pathogenesis of primary headaches. Infusion of NO donors can trigger headache attacks, and products of NO metabolism are found to be increased in the cranial circulation in patients suffering from such headaches. To examine if NO is involved in mediating and maintaining spinal trigeminal neuronal activity, an animal model of meningeal nociception was used. In barbiturate-anesthetized rats, a cranial window was made to expose the parietal dura mater. An access to the medullary brain stem allowed extracellular action potentials to be recorded from neurons in the spinal trigeminal nucleus that received afferent input from the exposed dura. Slow intravenous infusion of the NO donor, sodium nitroprusside (SNP, 50 microg/kg), transiently increased spontaneous activity in a subset of neurons and, with a latency of 50 min, caused a progressive increase in impulse activity across the entire sample of neurons. A similar pattern of delayed activation was seen after topical application of the same dose of SNP onto the exposed medulla. Slow injection of the nonspecific inhibitor of NO synthase, N(omega)-nitro-l-arginine methyl ester (20 mg/kg), reduced the spontaneous activity in all neurons within 15 min. The results suggest that NO can induce delayed, slowly developing activation of central trigeminal neurons and that endogenous release of NO may contribute to the ongoing activity of these neurons. The delayed changes in neuronal activity may include gene expression of pro-nociceptive mediators. These mechanisms may be relevant for the pathogenesis of chronic headaches.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115784     DOI: 10.1152/jn.01210.2003

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  21 in total

Review 1.  Update on animal models of migraine.

Authors:  Marcela Romero-Reyes; Simon Akerman
Journal:  Curr Pain Headache Rep       Date:  2014-11

Review 2.  Nitric oxide signalling in the brain and its control of bodily functions.

Authors:  Konstantina Chachlaki; Vincent Prevot
Journal:  Br J Pharmacol       Date:  2019-09-08       Impact factor: 8.739

Review 3.  Nitric oxide-related drug targets in headache.

Authors:  Jes Olesen
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 4.  Targeted Nitric Oxide Synthase Inhibitors for Migraine.

Authors:  Amynah A Pradhan; Zachariah Bertels; Simon Akerman
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

5.  Inhibition of the PKCγ-ε pathway relieves from meningeal nociception in an animal model: an innovative perspective for migraine therapy?

Authors:  Nicoletta Galeotti; Carla Ghelardini
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 6.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 7.  [What is needed to develop a headache? Anatomical and pathophysiological implications].

Authors:  U Reuter; A May
Journal:  Schmerz       Date:  2004-10       Impact factor: 1.107

Review 8.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

9.  Vascular extracellular signal-regulated kinase mediates migraine-related sensitization of meningeal nociceptors.

Authors:  XiChun Zhang; Vanessa Kainz; Jun Zhao; Andrew M Strassman; Dan Levy
Journal:  Ann Neurol       Date:  2013-06-17       Impact factor: 10.422

Review 10.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.